(SNN) Smith & Nephew SNATS - Overview

Sector: Healthcare | Industry: Medical Devices | Exchange: NYSE (USA) | Market Cap: 12.608m USD | Total Return: 7.9% in 12m

Joint Implants, Wound Dressings, Surgical Instruments, Medical Biologics
Total Rating 59
Safety 93
Buy Signal -0.14
Medical Devices
Industry Rotation: +4.2
Market Cap: 12.6B
Avg Turnover: 40.1M
Risk 3d forecast
Volatility26.4%
VaR 5th Pctl4.33%
VaR vs Median-0.33%
Reward TTM
Sharpe Ratio0.26
Rel. Str. IBD21.1
Rel. Str. Peer Group48.1
Character TTM
Beta0.173
Beta Downside0.003
Hurst Exponent0.534
Drawdowns 3y
Max DD32.36%
CAGR/Max DD0.11
CAGR/Mean DD0.29
EPS (Earnings per Share) EPS (Earnings per Share) of SNN over the last years for every Quarter: "2021-03": 0.1165, "2021-06": 0.78, "2021-09": 0, "2021-12": 0.36, "2022-03": 0, "2022-06": 0.2, "2022-09": 0, "2022-12": 0.05, "2023-03": 0, "2023-06": 0.35, "2023-09": 0, "2023-12": 1.31, "2024-03": 0, "2024-06": 0.756, "2024-09": 0, "2024-12": 0.23, "2025-03": 0, "2025-06": 0.33, "2025-09": 0, "2025-12": 0.38, "2026-03": 0,
EPS CAGR: -69.02%
EPS Trend: 0.9%
Last SUE: 0.00
Qual. Beats: 0
Revenue Revenue of SNN over the last years for every Quarter: 2021-03: 1299.5, 2021-06: 2599, 2021-09: 1306.5, 2021-12: 2613, 2022-03: 1300, 2022-06: 2600, 2022-09: 1307.5, 2022-12: 2615, 2023-03: 1367, 2023-06: 2734, 2023-09: 1407.5, 2023-12: 2815, 2024-03: 1413.5, 2024-06: 2827, 2024-09: null, 2024-12: 2983, 2025-03: null, 2025-06: 2987.725, 2025-09: null, 2025-12: 3190.67947, 2026-03: null,
Rev. CAGR: 5.62%
Rev. Trend: 38.9%
Qual. Beats: 0

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Description: SNN Smith & Nephew SNATS

Smith & Nephew (SNN) is a global medical technology company specializing in three primary segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The firm manufactures a diverse range of surgical implants, visualization technologies for minimally invasive procedures, and specialized treatments for chronic wounds and regenerative medicine. Founded in 1856, the company serves healthcare providers across international markets, focusing on joint replacement and soft tissue repair.

Operating within the Health Care Equipment sector, the company utilizes a business model driven by high research and development costs and strict regulatory compliance. This industry is characterized by high barriers to entry due to the technical complexity of surgical hardware and the necessity of long-term clinical data to secure market share. For deeper insights into these industry drivers, investors may wish to review the detailed metrics on ValueRay.

Headlines to Watch Out For
  • Orthopaedics segment recovery hinges on elective surgery volume and surgical robotics adoption
  • Sports Medicine revenue growth depends on global expansion of minimally invasive procedures
  • Advanced Wound Management margins face pressure from raw material and logistics inflation
  • Supply chain efficiency improvements are critical to meeting 2025 operating profit targets
  • Regulatory approval timelines for new implant technologies impact long-term market share gains
Piotroski VR‑10 (Strict) 9.0
Net Income: 1.04b TTM > 0 and > 6% of Revenue
FCF/TA: 0.14 > 0.02 and ΔFCF/TA 10.56 > 1.0
NWC/Revenue: 20.92% < 20% (prev 32.03%; Δ -11.11% < -1%)
CFO/TA 0.22 > 3% & CFO 2.28b > Net Income 1.04b
Net Debt (2.77b) to EBITDA (2.82b): 0.98 < 3
Current Ratio: 2.57 > 1.5 & < 3
Outstanding Shares: last quarter (436.5m) vs 12m ago -50.03% < -2%
Gross Margin: 68.80% > 18% (prev 0.70%; Δ 6.81k% > 0.5%)
Asset Turnover: 114.2% > 50% (prev 79.40%; Δ 34.78% > 0%)
Interest Coverage Ratio: 5.05 > 6 (EBITDA TTM 2.82b / Interest Expense TTM 329.4m)
Altman Z'' 5.42
A: 0.24 (Total Current Assets 4.10b - Total Current Liabilities 1.59b) / Total Assets 10.46b
B: 0.51 (Retained Earnings 5.32b / Total Assets 10.46b)
C: 0.16 (EBIT TTM 1.66b / Avg Total Assets 10.50b)
D: 1.07 (Book Value of Equity 5.52b / Total Liabilities 5.17b)
Altman-Z'' Score: 5.42 = AAA
Beneish M -3.02
DSRI: 0.74 (Receivables 1.43b/1.35b, Revenue 11.99b/8.37b)
GMI: 1.02 (GM 68.80% / 70.20%)
AQI: 1.02 (AQ_t 0.45 / AQ_t-1 0.44)
SGI: 1.43 (Revenue 11.99b / 8.37b)
TATA: -0.12 (NI 1.04b - CFO 2.28b) / TA 10.46b)
Beneish M-Score: -3.02 (Cap -4..+1) = AA
What is the price of SNN shares? As of May 21, 2026, the stock is trading at USD 31.01 with a total of 1,131,930 shares traded.
Over the past week, the price has changed by +3.99%, over one month by -9.35%, over three months by -12.87% and over the past year by +7.93%.
Is SNN a buy, sell or hold? Smith & Nephew SNATS has received a consensus analysts rating of 3.75. Therefor, it is recommend to hold SNN.
  • StrongBuy: 1
  • Buy: 1
  • Hold: 2
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the SNN price?
Analysts Target Price 35 12.8%
Smith & Nephew SNATS (SNN) - Fundamental Data Overview as of 19 May 2026
P/E Trailing = 20.6573
P/E Forward = 13.6799
P/S = 2.0697
P/B = 2.417
P/EG = 1.2113
Revenue TTM = 11.99b USD
EBIT TTM = 1.66b USD
EBITDA TTM = 2.82b USD
Long Term Debt = 3.03b USD (from longTermDebt, last quarter)
Short Term Debt = 150.0m USD (from shortTermDebt, last quarter)
Debt = 3.33b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.77b USD (from netDebt column, last quarter)
Enterprise Value = 15.38b USD (12.61b + Debt 3.33b - CCE 557.0m)
Interest Coverage Ratio = 5.05 (Ebit TTM 1.66b / Interest Expense TTM 329.4m)
EV/FCF = 10.53x (Enterprise Value 15.38b / FCF TTM 1.46b)
FCF Yield = 9.49% (FCF TTM 1.46b / Enterprise Value 15.38b)
FCF Margin = 12.18% (FCF TTM 1.46b / Revenue TTM 11.99b)
Net Margin = 8.66% (Net Income TTM 1.04b / Revenue TTM 11.99b)
Gross Margin = 68.80% ((Revenue TTM 11.99b - Cost of Revenue TTM 3.74b) / Revenue TTM)
Gross Margin QoQ = 65.56% (prev 70.62%)
Tobins Q-Ratio = 1.47 (Enterprise Value 15.38b / Total Assets 10.46b)
Interest Expense / Debt = 2.24% (Interest Expense 74.6m / Debt 3.33b)
Taxrate = 20.39% (84.7m / 415.6m)
NOPAT = 1.32b (EBIT 1.66b * (1 - 20.39%))
Current Ratio = 2.57 (Total Current Assets 4.10b / Total Current Liabilities 1.59b)
Debt / Equity = 0.63 (Debt 3.33b / totalStockholderEquity, last quarter 5.29b)
Debt / EBITDA = 0.98 (Net Debt 2.77b / EBITDA 2.82b)
Debt / FCF = 1.90 (Net Debt 2.77b / FCF TTM 1.46b)
Total Stockholder Equity = 5.32b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.89% (Net Income 1.04b / Total Assets 10.46b)
RoE = 19.51% (Net Income TTM 1.04b / Total Stockholder Equity 5.32b)
RoCE = 19.91% (EBIT 1.66b / Capital Employed (Equity 5.32b + L.T.Debt 3.03b))
RoIC = 15.46% (NOPAT 1.32b / Invested Capital 8.56b)
WACC = 5.59% (E(12.61b)/V(15.94b) * Re(6.59%) + D(3.33b)/V(15.94b) * Rd(2.24%) * (1-Tc(0.20)))
Discount Rate = 6.59% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares (quarterly) Correlation: -22.47 | Cagr: -26.39%
[DCF] Terminal Value 88.44% ; FCFF base≈1.02b ; Y1≈1.26b ; Y5≈2.15b
[DCF] Fair Price = 139.3 (EV 62.24b - Net Debt 2.77b = Equity 59.47b / Shares 426.8m; r=6.0% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 0.90 | EPS CAGR: -69.02% | SUE: 0.0 | # QB: 0
Revenue Correlation: 38.94 | Revenue CAGR: 5.62% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=1.94 | Chg30d=-5.17% | Revisions=+20% | GrowthEPS=-4.7% | GrowthRev=+6.8%
EPS next Year (2027-12-31): EPS=2.18 | Chg30d=+4.28% | Revisions=-20% | GrowthEPS=+12.1% | GrowthRev=+5.6%
[Analyst] Revisions Ratio: +20%